NASDAQ: BCPC · Specialty Chemicals
Balchem (BCPC) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Balchem (BCPC) at $160.63 a share. The stock last closed at $171.48, which puts the model's fair value 6.3% below the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 16 Nov 2026. Balchem Corp.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $164.26 to $160.63 (-2.2%). The model's quality adjustment to the peer multiple moved, lowering the fair value: most of the move.
What the model makes of itThe price of $171.48 is 6.3% above it: Fairly valued, on a high evidence grade.
What's nextNext report on 19 Feb 2027. Options prices imply a move of about 6% either way over the next month. On the model's Earnings Momentum list since 4 Nov 2026 (a strategy with a proving record). The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give BCPC?
The calibrated range for BCPC over 63 trading days is $159.53 to $184.99. It sits around the last close, and its width comes from the volatility that BCPC's own options imply (22% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $133.37 to $191.30. In 36% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Balchem Corporation develops, manufactures and distributes specialty performance ingredients and products worldwide, for markets including nutrition, food, pharmaceuticals, animal health and industrial use.
Faircurve's model put the fair value of Balchem Corp (BCPC) at $160.63 a share on 14 Nov 2026, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $164.26, so the fair value moved -2.2%. The model's quality adjustment to the peer multiple moved, lowering the fair value: most of the move. The calibrated range over 63 trading days is $159.53 to $184.99. Ranges built this way held the price 60% of the time at this horizon. The model grades the evidence High. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.
Balchem scores 86 out of 100 on the model's overall quality measure, a composite of six factors scored against comparable companies. Profitability scores 100, with ROIC of 13.1% against a peer median of 7.1%. The balance sheet also scores 100, with net debt to EBITDA of 0.28x against a peer median of 3.50x. Growth quality scores 87, with trailing revenue growth of 8.8% against a peer median of -2.7%. The model compares Balchem with Sensient Technologies Corporation (SXT), NewMarket Corporation (NEU), Avient Corporation (AVNT), Eastman Chemical Company (EMN), Element Solutions Inc (ESI), Westlake Corporation (WLK), Cabot Corp. (CBT) and Ashland Inc. (ASH).
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does BCPC report earnings, and how has the stock reacted?
Balchem's next earnings report is scheduled for 19 Feb 2027. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 5.1% in either direction through the nearest expiry, about 31 days out. That is the size the market is pricing, not a direction. BCPC's 30 day implied volatility works out to about 6.3% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across BCPC's last 8 reports, ignoring direction, was 2.1%.
What the options market has priced for a month's move in BCPC
How does BCPC score on business quality?
Balchem's overall quality score is 86 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 100 | 13.1%ROIC | 7.1% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 62 | 1.22xFCF / net income | 0.89x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 87 | 8.8%Revenue growth, trailing | -2.7% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 93 | 2.3%Net buybacks / market value | 1.3% |
| Balance sheetNet debt to EBITDA and interest coverage. | 100 | 0.28xNet debt / EBITDA | 3.50x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 71 | 1.1 ptsEBITDA margin downside volatility, 5y | 1.5 pts |
How does BCPC compare with similar companies?
The companies in specialty chemicals closest to Balchem in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| SXT Sensient Technologies Corporation | $114.59 | $109.66 | -4.3% | Fairly valued |
| NEU NewMarket Corporation | $696.68 | $684.14 | -1.8% | Fairly valued |
| AVNT Avient Corporation | $43.97 | $42.18 | -4.1% | Fairly valued |
| EMN Eastman Chemical Company | $63.49 | $65.16 | +2.6% | Fairly valued |
| ESI Element Solutions Inc | $31.75 | $30.70 | -3.3% | Fairly valued |
| WLK Westlake Corporation | $61.63 | $55.30 | -10.3% | Fairly valued |
| CBT Cabot Corp. | $70.92 | $78.89 | +11.2% | Fairly valued |
| ASH Ashland Inc. | $75.57 | $70.99 | -6.1% | Fairly valued |
What the comparable companies' multiples alone would give for BCPC, the peer-implied price, is $127.41 a share on this run. The fair value weighs that against the company's own multiple.
Balchem at a glance
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide.
- Market value
- $5.5B
- Sector
- Basic Materials
- Industry
- Specialty Chemicals
- Revenue expected, next twelve months
- $1.2B
- Consensus revenue growth, next fiscal year
- +9.2%
- Analysts with estimates
- 2
- Beta to the US market
- 0.13
- First valued by Faircurve
- 11 Jul 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. BCPC was not among them.
How the fair value is worked out: the model prices Balchem on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for BCPC was $164.26. As of 14 Nov 2026 it is $160.63, a change of -2.2%. The model's quality adjustment to the peer multiple moved, lowering the fair value: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Balchem's valuation
Is Balchem stock undervalued or overvalued?
On Faircurve's model, BCPC reads as Fairly valued as of 14 Nov 2026. The model's fair value is $160.63 a share against a last close of $171.48, a gap of -6.3%.
What is BCPC's fair value?
$160.63 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $133.37 to $191.30.
What price range does the model give BCPC?
$159.53 to $184.99 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Balchem report earnings next?
The next report is scheduled for 19 Feb 2027. Companies can move their dates.
How much has BCPC moved on past earnings reports?
Across its last 8 reports the median two session move was 2.1%, ignoring direction. The largest was -6.8% around the report of 30 Apr 2026.
How confident is the model in this valuation?
The model's evidence grade for BCPC is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on BCPC
The model has an idea open on BCPC under Earnings Momentum since 4 Nov 2026, a strategy with a proving record. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on BCPC with their outcomes. A free account is enough.